High-Grade Prostate Cancer: Favorable Results in the Modern Era Regardless of Initial Treatment
Table 1
Comparison of patient demographics and pretreatment features.
Surgery
Radiation
Hormone therapy
Total
value
Age
<0.0011
ā
216
59
129
404
āMean (SD)
64.6 (7.2)
70.9 (8.4)
77 (8.1)
69.5 (9.5)
Race, (%)
0.482
āWhite
161 (74.5)
40 (67.8)
92 (71.3)
293 (72.5)
āBlack
14 (6.5)
7 (11.9)
16 (12.4)
37 (9.2)
āOther
3 (1.4)
0 (0)
1 (0.8)
4 (1)
āUnknown
38 (17.6)
12 (20.3)
20 (15.5)
70 (17.3)
āTotal
216
59
129
404
Gleason score, (%)
0.372
ā8
84 (54.2)
33 (55.9)
63 (48.8)
180 (52.5)
ā9
67 (43.2)
22 (37.3)
57 (44.2)
146 (42.6)
ā10
4 (2.6)
4 (6.8)
9 (7)
17 (5)
āTotal3
155
59
129
343
PSA at diagnosis (ng/mL)
<0.0011
ā
208
57
126
391
āMean (SD)
10.3 (11.9)
15.5 (27.1)
48.2 (79.4)
23.3 (50)
Fraction of positive cores
<0.0011
ā
214
59
126
399
āMean (SD)
50% (30%)
40% (30%)
60% (30%)
50% (30%)
1Kruskal-Wallis Test. 2Pearsonās Chi-Square Test. 361 surgical patients had a Gleason score of <8 on biopsy but ā„8 on radical prostatectomy pathology and thus were included for analysis.